Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases

Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Blanco C, Crespo E, Gamo M, Villalobos L, Escribano P,

Keywords: TACE, TAE, GEP-NET,

#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms

Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Lopez C, Jimenez-Fonseca P, Matos I, Capdevila J,

Keywords: capecitabine, temozolomide, G3 NEN, Ki-67,

#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain

Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Crespo G, Jimenez-Fonseca P, Custodio A, Lopez C, Carmona-Bayonas A,

Keywords: capecitabine, temozolomide,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.